-
随着人口老龄化,我国的血管疾病问题日益突出,心血管疾病和脑血管疾病导致了高发病率和高死亡率。此外,由于生活方式和饮食习惯的明显改变,越来越多的年轻病人诊出血管疾病。研究[1]显示,动脉粥样硬化是导致心血管疾病、脑血管疾病和其他血管疾病的主要因素。而脑梗死是最常见的脑血管疾病,也是全世界死亡和致残的主要原因之一,其发病率为每100万人中100~200人,其中10%~14%的病人年龄在18~45岁之间[2]。动脉粥样硬化是一个包括炎症、胶原基质积累和DNA异常甲基化的复杂过程[3]。同型半胱氨酸(homocysteine, HCY) 参与蛋氨酸循环和转移甲基化过程,从而干扰DNA甲基化[4]。本研究探讨腔隙性脑梗死病人颈动脉粥样硬化(carotid artery arteriosclerosis,CAS)与血同型半胱氨酸(HCY)水平的关系,旨在为临床脑血管疾病的早期防治提供理论依据。现作报道。
-
CAS组病人年龄、高血压和高效C反应蛋白(hs-CRP)、HCY水平及基线收缩压(SBP)、舒张压(DBP)与非CAS组差异均有统计学意义(P < 0.05~P < 0.01)(见表 1)。
分组 n 年龄/岁 男性 糖尿病 高血压 高脂血症 冠心病 吸烟 饮酒 LDL-C HDL-C hs-CRP 基线SBP/mmHg 基线DBP/mmHg HCY/(mmol/L) CAS组 100 69.66±9.16 44(44.0) 13(13.0) 75(75.0) 28(28.0) 53(53.0) 45(45.0) 42(42.0) 3.27±1.30 1.30±0.26 4.58±4.02 134.78±23.34 84.68±21.24 19.76±2.11 非CAS组 100 66.72±8.40 49(49.0) 10(10.0) 57(57.0) 23(23.0) 50(50.0) 40(40.0) 44(44.0) 3.15±1.29 1.31±0.26 2.42±2.21 124.04±18.51 74.66±17.20 16.81±1.37 χ2 — 2.37Δ 0.5 0.44 7.22 0.66 0.18 0.51 0.08 0.66Δ 0.27Δ 4.71Δ 3.61Δ 3.67Δ 11.73Δ P — < 0.05 >0.05 >0.05 < 0.01 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 < 0.01 < 0.01 < 0.01 < 0.01 Δ示t值 表 1 CAS组和非CAS组病人相关指标比较[n;百分率(%)]
-
斑块组病人血清HCY水平均明显高于增厚组和正常组(P < 0.01),增厚组HCY水平亦明显高于正常组(P < 0.01)(见表 2)。
分组 n HCY/(mmol/L) F P MS组内 正常组 100 15.25±1.14 增厚组 59 17.93±1.11** 1 001.47 < 0.01 1.338 斑块组 41 24.85±1.26**## q检验:与正常组比较**P < 0.01;与增厚组比较##P < 0.01 表 2 不同CIMT组病人血清HCY水平比较(x±s)
-
低HCY组病人CIMT为(0.75±0.10)mm,明显低于高HCY组的(1.26±0.13)mm(t=31.24,P < 0.01)。
-
以有无CAS为因变量,有CAS赋值1,无CAS赋值0,以单因素分析中有意义变量年龄、高血压、基线SBP、基线DBP、HCY、hs-CRP为自变量进行二分类的logistic回归分析,自变量的筛选方法选用LR法,结果显示,年龄、高血压、hs-CRP、HCY均为CAS发生的独立影响因素(P < 0.05~P < 0.01)(见表 3)。
变量 B SE Waldχ2 P OR(95%CI) 年龄 0.05 0.02 5.27 < 0.05 1.049(1.01~1.09) 高血压 1.26 0.38 10.81 < 0.01 3.539(1.67~7.52) hs-CRP 0.31 0.06 25.24 < 0.01 1.365(1.21~1.54) 基线SBP -0.01 0.04 0.03 >0.05 0.993(0.92~1.07) 基线DBP 0.04 0.04 1.04 >0.05 1.045(0.96~1.14) HCY 0.08 0.02 14.34 < 0.01 1.086(1.04~1.13) 表 3 影响CAS的多因素logistic回归分析
腔隙性脑梗死病人颈动脉粥样硬化与血同型半胱氨酸关系及其危险因素研究
Study on the relationship between carotid artery atherosclerosis and blood homocysteine, and its risk factors in patients with lacunar cerebral infarction
-
摘要:
目的探讨腔隙性脑梗死病人颈动脉粥样硬化(CAS)与血同型半胱氨酸(HCY)的相关性及其危险因素。 方法纳入腔隙性脑梗死病人200例,所有病人均行颈动脉超声检查和血HCY测定,根据颈动脉超声检查结果和血HCY水平进行分组,采用单因素分析和多因素logistic回归分析分析CAS的危险因素及与血HCY关系。 结果CAS组病人年龄、高血压和高敏C反应蛋白(hs-CRP)、HCY水平及基线收缩压(SBP)、舒张压(DBP)与非CAS组差异均有统计学意义(P < 0.05~P < 0.01)。CIMT斑块组病人血清HCY水平均明显高于CIMT增厚组和正常组(P < 0.01),CIMT增厚组HCY水平亦明显高于正常组(P < 0.01)。低HCY组病人CIMT为(0.75±0.10)mm,明显低于高HCY组的(1.26±0.13)mm(P < 0.01)。Logistic回归分析结果显示,年龄、高血压、hs-CRP、HCY均为发生CAS的独立影响因素(P < 0.05~P < 0.01)。 结论除年龄、高血压、hs-CRP影响CAS的发生外,血HCY水平同样影响CAS的发生,临床可针对这些危险因素对CAS进行早期评估和预防。 Abstract:ObjectiveTo investigate the relationship between carotid artery atherosclerosis(CAS) and blood homocysteine(HCY), and its risk factors in patients with lacunar cerebral infarction. MethodsThe carotid artery ultrasound and serum levels of HCY in 200 patients with lacunar cerebral infarction were detected.According to the results of carotid ultrasound examination and blood HCY level, the patients were grouped, and the risk factors of CAS and their relationship with blood HCY were analyzed using univariate analysis and multivariate logistic regression analysis. ResultsThe differences of the age, hypertension history, levels of hs-CRP and HCY, baseline SBP and SDP between non-CAS group and CAS group were statistically significant(P < 0.05 to P < 0.01).the serum level of HCY in CIMT plaque group was significantly higher than that in CIMT thickening group and normal group(P < 0.01), and the HCY level in CIMT thickening group was also significantly higher than that in normal group(P < 0.01).The CIMT in low HCY group[(0.75±0.10) mm] was significantly lower than that in high HCY group[(1.26±0.13) mm](P < 0.01).The results of multiple logistic regression analysis showed that the age, hypertension history, hs-CRP and HCY were the independent influencing factors of CAS(P < 0.05 to P < 0.01). ConclusionsIn addition to age, hypertension and HS-CRP, the blood HCY level also affects the occurrence of CAS.Early assessment and prevention of CAS can be carried out clinically based on these risk factors. -
Key words:
- infarction /
- carotid artery arteriosclerosis /
- homocysteine
-
表 1 CAS组和非CAS组病人相关指标比较[n;百分率(%)]
分组 n 年龄/岁 男性 糖尿病 高血压 高脂血症 冠心病 吸烟 饮酒 LDL-C HDL-C hs-CRP 基线SBP/mmHg 基线DBP/mmHg HCY/(mmol/L) CAS组 100 69.66±9.16 44(44.0) 13(13.0) 75(75.0) 28(28.0) 53(53.0) 45(45.0) 42(42.0) 3.27±1.30 1.30±0.26 4.58±4.02 134.78±23.34 84.68±21.24 19.76±2.11 非CAS组 100 66.72±8.40 49(49.0) 10(10.0) 57(57.0) 23(23.0) 50(50.0) 40(40.0) 44(44.0) 3.15±1.29 1.31±0.26 2.42±2.21 124.04±18.51 74.66±17.20 16.81±1.37 χ2 — 2.37Δ 0.5 0.44 7.22 0.66 0.18 0.51 0.08 0.66Δ 0.27Δ 4.71Δ 3.61Δ 3.67Δ 11.73Δ P — < 0.05 >0.05 >0.05 < 0.01 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 < 0.01 < 0.01 < 0.01 < 0.01 Δ示t值 表 2 不同CIMT组病人血清HCY水平比较(x±s)
分组 n HCY/(mmol/L) F P MS组内 正常组 100 15.25±1.14 增厚组 59 17.93±1.11** 1 001.47 < 0.01 1.338 斑块组 41 24.85±1.26**## q检验:与正常组比较**P < 0.01;与增厚组比较##P < 0.01 表 3 影响CAS的多因素logistic回归分析
变量 B SE Waldχ2 P OR(95%CI) 年龄 0.05 0.02 5.27 < 0.05 1.049(1.01~1.09) 高血压 1.26 0.38 10.81 < 0.01 3.539(1.67~7.52) hs-CRP 0.31 0.06 25.24 < 0.01 1.365(1.21~1.54) 基线SBP -0.01 0.04 0.03 >0.05 0.993(0.92~1.07) 基线DBP 0.04 0.04 1.04 >0.05 1.045(0.96~1.14) HCY 0.08 0.02 14.34 < 0.01 1.086(1.04~1.13) -
[1] TOWFIGHI A, SAVER JL.Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead[J]. Stroke, 2011, 42(8): 2351. doi: 10.1161/STROKEAHA.111.621904 [2] JI R, SCHWAMM LH, PERVEZ MA, et al. Ischemic stroke and transient ischemic attack in young adults: risk factors, diagnostic yield, neuroimaging, and thrombolysis[J]. JAMA Neurol, 2013, 70(1): 51. doi: 10.1001/jamaneurol.2013.575 [3] THOMAS MR, LIP GYH.Novel risk markers and risk assessments for cardiovascular disease[J]. Circulation Res, 2017, 120(1): 133. doi: 10.1161/CIRCRESAHA.116.309955 [4] HANNIBAL L, BLOM HJ.Homocysteine and disease: causal associations or epiphenomenons?[J]. Mol Aspects Med, 2016, 53: 36. [5] JIANG XG, LIN Y, LI YS.Correlative study on risk factors of depression among acute stroke patients[J]. Eur Rev Med Pharmacol Sci, 2014, 18(9): 1315. [6] BALDASSARRE D, AMATO M, BONDIOLI A, et al. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors[J]. Stroke, 2000, 31(10): 2426. doi: 10.1161/01.STR.31.10.2426 [7] ELKIND MS, CHENG J, BODEN-ALBALA B, et al. Elevated white blood cell count and carotid paque thickness: the northern manhattan stroke study[J]. Stroke, 2001, 32(4): 842. doi: 10.1161/01.STR.32.4.842 [8] SIMON A, GARIEPY J, CHIRONI G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk[J]. J Hypertens, 2002, 20(2): 159. doi: 10.1097/00004872-200202000-00001 [9] BARTON M.Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?[J]. Expert Opin Investig Drugs, 2001, 10(5): 789. doi: 10.1517/13543784.10.5.789 [10] MAGNANI G, DEMOLA MA, FAVA C, et al. From vulnerable plaque to vulnerable patient[J]. G Ital Cardiol, 2010, 11(3): 6S. [11] PRETORIUS E, ROOY MJV.Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events[J]. Curr Med Chem, 2014, 21(19): 2121. doi: 10.2174/0929867321666131227162950 [12] SKOVIEROVÁ H, VIDOMANOVÁ E, SILVIA M, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health[J]. Int J Mol Sci, 2016, 17(10): 1733. doi: 10.3390/ijms17101733 [13] GREGOIRE SM, SCHEFFLER G, JAGER HR, et al. Strictly lobar microbleeds are associated with executive impairment in patients with ischemic stroke or transient ischemic attack[J]. Stroke, 2013, 44(5): 1267. doi: 10.1161/STROKEAHA.111.000245 [14] MIWA K, TANAKA M, OKAZAKI S, et al. Relations of blood inflammatory marker levels with cerebral microbleeds[J]. Stroke, 2011, 42(11): 3202. doi: 10.1161/STROKEAHA.111.621193 [15] DEVASIA AJ, JOY B, TAREY SD.Serum homocysteine as a risk factor for carotid intimal thickening in acute stroke: a cross sectional observational study[J]. Ann Indian Acad Neurol, 2016, 19(1): 48. doi: 10.4103/0972-2327.168633 [16] BREE AD, MENNEN LI, ZUREIK M, et al. Homocysteine is not associated with arterial thickness and stiffness in healthy middle-aged French volunteers[J]. Int J Cardiol, 2006, 113(3): 340. [17] MEYE C, SCHUMANN J, WAGNER A, et al. Effects of homocysteine on the levels of caveolin-1 and eNOS in caveolae of human coronary artery endothelial cells[J]. Atherosclerosis, 2007, 190(2): 256. doi: 10.1016/j.atherosclerosis.2006.03.009 [18] ALBA FS, SERGI SB, ISAAC S, et al. Association between DNA methylation and coronary heart disease or other atherosclerotic events: a systematic review[J]. Atherosclerosis, 2017, 263: 325. doi: 10.1016/j.atherosclerosis.2017.05.022 [19] HUMPHREY LL, FU R, ROGERS K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis[J]. Mayo Clin Proc, 2008, 83(11): 1203. doi: 10.4065/83.11.1203 [20] KRISHNA SM, DEAR A, CRAIG JM, et al. The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation[J]. Atherosclerosis, 2013, 228(2): 295. doi: 10.1016/j.atherosclerosis.2013.02.019 [21] KIM JM, PARK KY, SHIN DW, et al. Relation of serum homocysteine levels to cerebral artery calcification and atherosclerosis[J]. Atherosclerosis, 2016, 254: 200. doi: 10.1016/j.atherosclerosis.2016.10.023 [22] CATENA C, COLUSSI GL, MARION UM, et al. Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension[J]. J Am Soc Hypertens, 2015, 9(3): 167. doi: 10.1016/j.jash.2014.12.020 [23] SARA A, HANNAH G, ELKIND MSV, et al. Elevated homocysteine and carotid plaque area and densitometry in the Northern Manhattan study[J]. Stroke, 2013, 44(2): 457. doi: 10.1161/STROKEAHA.112.676155